

Special Issue

State-of-the-Art Cancer Biology, Bidiagnostics and Therapeutics in Japan—Second Edition

Message from the Guest Editors

In this Special Issue, we are seeking original research articles or review submissions that present impactful advances in the development of cancer biology, diagnostics, and therapeutics in relation to one or more of, but not limited to, the following topics:

- Cancer biology;
- Molecular mechanisms of cancers;
- Cancer epigenetics;
- Resistance mechanism to conventional therapies;
- Cancer biomarkers;
- Early cancer detection;
- Clinical investigations;
- Cancer diagnostics;
- Novel therapeutics;
- Novel paradigms in cancer diagnosis and treatment.

Guest Editors

Dr. Takaaki Hirotsu

Hirotsu Bio Science Inc., Chiyoda-Ku, Tokyo 102-0094, Japan

Dr. Eric Di Luccio

Hirotsu Bioscience Inc., New Otani Garden Court 22F, 4-1 Kioi-cho, Chiyoda-ku, Tokyo 102-0094, Japan

Prof. Dr. Hideshi Ishii

Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Suita, Japan

Deadline for manuscript submissions

31 July 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/266576

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).